Form 4: PLUS THERAPEUTICS Director Buys 110,000 Shares

PLUS THERAPEUTICS Director Robert P. Lenk acquired 110,000 shares of common stock at $0.4889 per share in a pre-planned transaction.

Summary

• Robert P. Lenk, a Director of PLUS THERAPEUTICS, INC. (PSTV), purchased 110,000 shares of the company's common stock.
• The transaction occurred on August 22, 2025, at a price of $0.4889 per share.
• This purchase was made pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged trading plan.
• Following this transaction, Mr. Lenk directly beneficially owns 139,327 shares of PLUS THERAPEUTICS common stock.

Sentiment

Score: 7

Explanation: The purchase of a significant number of shares by a director indicates strong insider confidence, which is generally a positive signal for investors. The pre-planned nature (10b5-1) suggests a strategic, rather than reactive, investment.

Positives

• A company director, Robert P. Lenk, increased his direct ownership in PLUS THERAPEUTICS by purchasing 110,000 shares.
• The purchase was made at a price of $0.4889 per share, indicating a specific valuation point for the insider.
• The transaction was executed under a Rule 10b5-1(c) plan, suggesting a pre-planned investment strategy rather than a reaction to immediate market events.

Future Outlook

This filing does not contain forward-looking statements or guidance.

Industry Context

Insider purchases, especially by directors, can signal confidence in the company's future prospects, potentially indicating that management believes the stock is undervalued or that positive developments are anticipated. This is a common signal observed across various industries, particularly in the biotechnology sector where future catalysts are often key drivers.

Comparison to Industry Standards

• Insider buying, particularly by a director, is generally viewed positively by the market as it aligns management's interests with shareholders. For example, similar director purchases have been observed in biotech companies like BioNTech (BNTX) or Moderna (MRNA) where executives increase holdings ahead of clinical trial results or product launches, signaling confidence.
• The volume of 110,000 shares represents a significant personal investment at the stated price, which can be compared to average insider transaction sizes in the pharmaceutical/biotech sector, often indicating a strong conviction.

Stakeholder Impact

• Shareholders: May view the director's purchase as a positive signal, potentially increasing confidence in the stock and its future prospects.

Key Dates

Recommendation

The significant purchase of 110,000 shares by a director, Robert P. Lenk, at $0.4889 per share, signals strong insider confidence in PLUS THERAPEUTICS' future. Such insider buying, particularly when executed under a Rule 10b5-1 plan, suggests a strategic belief in the company's long-term value and prospects, making it an attractive signal for potential investors.

Keywords

PLUS THERAPEUTICS, PSTV, Insider Trading, Form 4, Director Purchase, Stock Acquisition, Robert P. Lenk, Equity, Beneficial Ownership, Rule 10b5-1